| Literature DB >> 31729254 |
Dimitrios Trafalis1, Panagiotis Dalezis1, Elena Geromichalou1, Sofia Sagredou1, Eleni Sflakidou2, Maria Voura2, Margarita Grammatikopoulou2, Catherine Gabriel3, Vasiliki Sarli2.
Abstract
Aim: Steroidal prodrugs of nitrogen mustards such as estramustine and prednimustine have proven effective anticancer agents in clinical use since the 1970s. In this work, we aimed to develop steroidal prodrugs of the novel nitrogen mustard POPAM-NH2. POPAM-NH2 is a melphalan analogue that was coupled with three different steroidal lactams. Methodology: The new conjugates were preclinically tested for anticancer activity against nine human and one rodent cancer experimental models, in vitro and in vivo. Results & conclusion: All the steroidal alkylators showed high antitumor activity, in vitro and in vivo, in the experimental systems tested. Moreover, these hybrid compounds showed by far superior anticancer activity compared with the alkylating agents, melphalan and POPAM-NH2.Entities:
Keywords: alkylating agent; homo-aza-steroidal alkylators; human cancer cell lines; melphalan; nitrogen mustard; steroidal lactam
Year: 2019 PMID: 31729254 DOI: 10.4155/fmc-2019-0255
Source DB: PubMed Journal: Future Med Chem ISSN: 1756-8919 Impact factor: 3.808